<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297570</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-06-4015-IH-CTIL</org_study_id>
    <nct_id>NCT00297570</nct_id>
  </id_info>
  <brief_title>Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+
      CML) patients with complete cytogenetic response after more than one year of imatinib
      therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN)
      to imatinib, in terms of the rate of achievement, molecular remission, and response duration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Leukemia, Myeloid, Philadelphia-Positive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon and Imatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of
             imatinib therapy.

        Exclusion Criteria:

          -  Patients in imatinib study

          -  Patients with a history of intolerability to interferon.

          -  Patients with less than CCR or less than one year of imatinib therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Izhar Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Izhar Hardan, MD</last_name>
    <phone>+972 3 5302174</phone>
    <email>izhar.hardan@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Izhar Hardan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>October 7, 2007</last_update_submitted>
  <last_update_submitted_qc>October 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <keyword>CML</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Pegylated Interferon</keyword>
  <keyword>Philadelphia Positive CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

